COVID-19: the use of immunotherapy in metastatic lung cancer

Field	Value	Language
dc.contributor.author	Davis, Alexander P	en
dc.contributor.author	Boyer, Michael	en
dc.contributor.author	Lee, Jenny H	en
dc.contributor.author	Kao, Steven C	en
dc.date.accessioned	2020-05-27
dc.date.available	2020-05-27
dc.date.issued	2020	en
dc.identifier.uri	https://hdl.handle.net/2123/22381
dc.description.abstract	Significant gains have been made in lung cancer morbidity and mortality since the introduction of PD-1 therapy. These benefits still exist in the ongoing COVID-19 pandemic, however, ongoing treatment may place a subset of patients at increased risk	en
dc.language.iso	en	en
dc.rights	Other
dc.subject	COVID-19	en
dc.subject	Coronavirus	en
dc.title	COVID-19: the use of immunotherapy in metastatic lung cancer	en
dc.type	Article	en
dc.identifier.doi	10.2217/imt-2020-0096
dc.relation.other	Takeda (United States)	en
dc.relation.other	Amgen (United States)	en
dc.relation.other	Boehringer Ingelheim (United States)	en
dc.relation.other	Bristol-Myers Squibb (United States)	en
dc.relation.other	MSD (United States)	en
dc.relation.other	Pfizer (United Kingdom)	en
dc.relation.other	Roche (United States)	en
dc.relation.other	AstraZeneca (United Kingdom)	en
usyd.faculty	Faculty of Medicine and Health, Sydney Medical School	en

Associated file/s

There are no files associated with this item.